| Secondary |
| Neoplasm Malignant |
22.8% |
| Product Used For Unknown Indication |
17.2% |
| Prophylaxis |
11.1% |
| Acute Lymphocytic Leukaemia |
8.2% |
| Stem Cell Transplant |
6.3% |
| Acute Promyelocytic Leukaemia |
4.8% |
| T-cell Type Acute Leukaemia |
4.7% |
| Adult T-cell Lymphoma/leukaemia |
3.8% |
| Infection Prophylaxis |
3.1% |
| Lymphoma |
2.3% |
| Drug Use For Unknown Indication |
2.1% |
| Acute Myeloid Leukaemia |
2.1% |
| Acute Myeloid Leukaemia Recurrent |
2.1% |
| Febrile Neutropenia |
1.8% |
| Prophylaxis Of Nausea And Vomiting |
1.6% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
1.3% |
| Chronic Myeloid Leukaemia |
1.3% |
| B-cell Lymphoma |
1.2% |
| Constipation |
1.2% |
| Mycosis Fungoides |
1.2% |
|
| White Blood Cell Count Decreased |
16.9% |
| Myelodysplastic Syndrome |
10.2% |
| Thrombocytopenia |
8.5% |
| Vomiting |
8.5% |
| Pancytopenia |
5.1% |
| Pneumonia |
5.1% |
| Pyrexia |
5.1% |
| Renal Failure Acute |
5.1% |
| Stomatitis |
5.1% |
| Febrile Neutropenia |
4.2% |
| Sepsis |
4.2% |
| Treatment Related Secondary Malignancy |
3.4% |
| Tumour Lysis Syndrome |
3.4% |
| Diarrhoea |
2.5% |
| Leukoencephalopathy |
2.5% |
| Pleural Effusion |
2.5% |
| Stevens-johnson Syndrome |
2.5% |
| Azoospermia |
1.7% |
| Cardiac Failure |
1.7% |
| Disease Progression |
1.7% |
|
| Concomitant |
| Neoplasm Malignant |
37.7% |
| Acute Myeloid Leukaemia |
8.8% |
| Drug Use For Unknown Indication |
7.9% |
| Prophylaxis |
6.6% |
| Acute Lymphocytic Leukaemia |
5.6% |
| T-cell Type Acute Leukaemia |
4.9% |
| Infection Prophylaxis |
3.4% |
| Myelodysplastic Syndrome |
2.8% |
| Product Used For Unknown Indication |
2.7% |
| Packed Red Blood Cell Transfusion |
2.6% |
| Platelet Transfusion |
2.6% |
| Stem Cell Transplant |
2.6% |
| Chronic Myeloid Leukaemia |
2.4% |
| Acute Promyelocytic Leukaemia |
1.5% |
| Convulsion Prophylaxis |
1.4% |
| Immunosuppression |
1.4% |
| Sepsis |
1.4% |
| B-cell Lymphoma |
1.3% |
| Infection |
1.3% |
| Prophylaxis Against Graft Versus Host Disease |
1.1% |
|
| White Blood Cell Count Decreased |
22.1% |
| Sepsis |
11.4% |
| Pleural Effusion |
10.7% |
| Cytomegalovirus Viraemia |
6.7% |
| Systemic Candida |
5.4% |
| Pulmonary Alveolar Haemorrhage |
4.7% |
| Engraft Failure |
4.0% |
| Febrile Neutropenia |
4.0% |
| Purpura |
3.4% |
| Renal Disorder |
3.4% |
| Respiratory Failure |
3.4% |
| Rhabdomyolysis |
3.4% |
| Torsade De Pointes |
3.4% |
| Acute Myeloid Leukaemia |
2.0% |
| Fungaemia |
2.0% |
| Memory Impairment |
2.0% |
| Myelodysplastic Syndrome |
2.0% |
| Pneumonia |
2.0% |
| Pulmonary Hypertension |
2.0% |
| Pyrexia |
2.0% |
|
| Interacting |
| Acute Myeloid Leukaemia |
28.8% |
| Prophylaxis |
28.8% |
| Febrile Neutropenia |
17.3% |
| Drug Use For Unknown Indication |
11.5% |
| Antifungal Prophylaxis |
7.7% |
| Menorrhagia |
5.8% |
|
| Drug Interaction |
40.0% |
| Menorrhagia |
40.0% |
| Device Occlusion |
20.0% |
|
